Page 2
-
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biotech generally underperformed the market so far this year. Updates from Amgen, Roche and Novartis could deliver a needed boost, analysts at Credit Suisse say.
-
Pharma's reputation among Americans sinks to lowest level in decades: poll
According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.
-
Novartis secures NICE nod for Luxturna with discount offer
The U.K. cost agency recommended Luxturna after reaching a deal with Novartis, which sells the Spark gene therapy outside the U.S.
-
Vertex to buy preclinical biotech for $950M, searching a Type 1 diabetes cure
Acquiring Semma Therapeutics fulfills CEO Jeffrey Leiden's promise that Vertex would explore "potentially larger" deals than it's done in the past.
-
Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals
Data show inclisiran more or less matched Repatha and Praluent on cholesterol lowering, but the drug will need a smart launch, and possibly a partner, to compete.
UPDATED: Sept. 3, 2019 at 10:07 a.m. -
Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters
Found in many solid tumors, mutant KRAS is cancer research's white whale. Amgen's drug looks the most promising to emerge from decades of failed efforts, but others are close behind.
-
Novartis vies for multiple sclerosis dominance with Arzerra trial
The repurposed cancer drug is aiming at Roche's Ocrevus, but an upcoming full data presentation will tell MS specialists more about its promise.
-
Deep DiveAmyloid's last hope? Prevention studies next big test for Alzheimer's research
The DIAN-TU trial, studying patients genetically predisposed to Alzheimer's, could help decide the fate of what's been the dominant hypothesis of the disease's cause.
-
UniQure stays a step ahead in hemophilia B
Seeing high interest from patients and study investigators, uniQure is enrolling six more participants than planned in its Phase 3 gene therapy study.
-
Alexion shares slide on Amgen patent challenge to top-seller
A surprise decision by the U.S. patent office to review three patents held by Alexion on its drug Soliris renewed fears of earlier-than-expected competition.
-
AbbVie ends Rova-T research after another study setback
A string of clinical failures derailed AbbVie's ambitions for the cancer drug, which was once predicted to earn billions of dollars in peak sales.
-
Catalent's legacy business outshined by acquisitions
The recent additions of Cook Pharmica, Juniper and Paragon are driving more revenue growth than the contract manufacturer's base business.
-
Deep DiveUnblinded: Rebekah Gee's drug pricing experiment in Louisiana
Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?
-
AstraZeneca gets lupus win but past failure could slow progress
A miss in anifrolumab's first Phase 3 trial a year ago raises questions over whether regulators will need a third study to see the drug through to market.
-
Amgen patents on Repatha invalid, judge rules in reversal
The decision by Judge Richard Andrews overturns a February jury verdict that affirmed two patents held by Amgen on the cholesterol drug.
-
FDA issues safety warning for newer hepatitis C drugs following patient deaths
More than 60 cases filed in the FAERS database detail how patients experienced worsening liver health after taking AbbVie's Mavyret, Merck & Co.'s Zepatier or Gilead's Vosevi.
-
Immatics shows Celgene isn't done stocking cell therapy pipeline
As its takeover by Bristol-Myers nears closing, Celgene is committing $75 million to research into T-cell redirecting technology.
-
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Out-of-pocket spending on MS medications increased by more than 600% in the decade from 2006 to 2016, while the typical list price quadrupled.
-
Purdue offering as much as $12 billion to settle opioid claims: report
The Oxycontin maker would reportedly declare Chapter 11 bankruptcy, becoming a public trust in which profits from drug sales would go to plaintiffs.
-
Biopharma jobs boom in Massachusetts, though challenges still exist
Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.
-
Gene editing companies oppose altering of embryos
Editing should be restricted to altering faulty genes in tissues, said Sangamo, Bluebird bio and 11 other biotechs in a statement of principles.
UPDATED: Aug. 27, 2019 at 12:43 p.m. -
Amgen buying Celgene's Otezla in $13B deal
The acquisition, which gives Amgen a complement to its top-seller Enbrel, is the biotech's largest since a 2002 deal to buy Immunex.
UPDATED: Aug. 26, 2019 at 12:16 p.m. -
Oklahoma judge orders J&J pay $572M in landmark opioid case
At issue was J&J's marketing of opioids Duragesic and Nucynta, as well as its supplying of API to other manufacturers via subsidiaries Noramco and Tasmanian Alkaloids.
-
Medicines Co.'s PCSK9 drug succeeds in first Phase 3 test
Positive results are a "major milestone," said one Wall Street analyst, easing safety concerns and setting up the biotech to file for approval this year.
-
Lilly's case for Taltz helped by expanded approval
By prescription numbers, Taltz trails Novartis' rival drug Cosentyx. An approval for use in ankylosing spondylitis will go some ways to level the playing field.
Home
